– Morgan Stanley Conf
Celldex Therapeutics Q3 EPS $(0.45) Down From $(0.36) YoY, Sales $153.00K Down From $668.00K YoY
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.45) per share. This is a 25 percent decrease over losses of $(0.36) per share from the same period last year. The company reported $153.00 thousand in